跳到正文
PharmTech Quality Systems·AI 评分37

AAPS PharmSci 360 2026:USP专家谈E&L标准协调的实践内涵

AAPS PharmSci 360 2026: E&L Standards Harmonization

AI 导读

USP高级首席科学家Ravi Kiran Kaja在AAPS PharmSci 360 2026前受访表示,E&L检测的科学原理不变,但风险与技术挑战随剂型而异,注射剂和眼用制剂需高灵敏度评估,吸入与鼻用制剂因装置成为产品系统的一部分而更复杂,透皮和局部制剂涉及复杂处方、黏合剂及长期包装接触,因此不能采用一刀切方法。

正文 · 原文

Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.

Ahead of AAPS PharmSci 360, PharmTech spoke with Ravi Kiran Kaja, senior principal scientist at the United States Pharmacopeia (USP), about how extractables and leachables (E&L) assessment differs by dosage form and what harmonization of E&L standards means in practice.

The scientific principles of E&L testing stay the same, explains Kaja, but the risks and technical challenges vary across dosage forms. Parenteral and ophthalmic products need very sensitive assessments because materials may come into direct contact with highly sensitive tissues. Inhalation and nasal products are more complex because the device itself often becomes part of the product system. Transdermal and topical products can involve complex formulations, adhesives and long-term contact with packaging. That is why a one-size-fits-all approach does not work in E&L science. Instead, testing must be tailored to the product, the route of administration, patient exposure, and the materials of construction. USP’s dosage form–specific chapters reflect this. As Kaja puts it, the analytical tools may be similar, but the scientific questions are different.

When it comes to harmonization, laboratories worldwide should produce data that are scientifically comparable and equally trusted. Harmonization relies on agreement on terminology, study design, analytical expectations, reference materials, and standards. It also takes collaboration among regulators, industry, standards organizations, and scientists. USP provides documentary standards, physical reference materials, scientific leadership, and forums for collaboration. Its System Suitability Initiative is one example. Harmonization, he stresses, is not uniformity; it is building global confidence in the quality of data.

Kaja will be presenting recent USP developments in E&L standards and complex products at AAPS PharmSci 360, and will be moderating the presentation, Seeing Inside the Dose: Predictive Drug Development with Microstructure Intelligence, which will be held on Wednesday, October 28.

More about this keynote session:

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1

https://www.pharmtech.com/view/aaps-pharmsci-360-microstructure-intelligence-in-predictive-drug-development-part-1

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 2

https://www.pharmtech.com/view/aaps-pharmsci-360-microstructure-intelligence-in-predictive-drug-development-part-2

Related to this article

PharmTech Weekly Roundup—October 30, 2026: Formulation, AI, and NAMs at AAPS PharmSci 360

October 30th, 2026

The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.

Read more

Manish Baviskar, senior validation engineer, Hubot CDMO

October 30th, 2026

Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.

Read more

Manish Baviskar, senior validation engineer, Hubot CDMO

October 29th, 2026

Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.

Read more

AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data

October 27th, 2026

Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.

Read more

AAPS PharmSci 360 2026: AI Tools, Regulations, and Preparedness

October 27th, 2026

Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.

Read more

AAPS PharmSci 360 2026: Roller-Compacted Formulations

October 26th, 2026

Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.

Read more

PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization

October 26th, 2026

This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.

Read more

Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight

October 23rd, 2026

Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.

Read more

来源:PharmTech Quality Systems · pharmtech.com